- Reaction score
- 1,779
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option.
Every day in the United States, approximately 17.5 veterans die by suicide, while 7% of veterans are diagnosed each year with post-traumatic stress disorder (PTSD). Against this backdrop, researchers at Texas A&M Health are helping advance a more personalized approach to treating PTSD.
A system developed by California-based Wave Neuroscience in collaboration with the research team of Dr. Kenneth S. Ramos at the Texas A&M Health Institute of Biosciences and Technology recently received FDA clearance. The technology maps brain activity associated with PTSD and uses those measurements to personalize treatment. The clinical findings are still being prepared for public dissemination, but preliminary results reported by the company suggest substantial improvements in PTSD symptoms.
PTSD can develop after exposure to events that go beyond ordinary stress, including combat, accidents, natural disasters, or other forms of violence. About 6% of people develop PTSD symptoms during their lifetimes, with substantially higher rates among women and veterans.
Since PTSD became an official diagnosis in 1980, common treatments have included talk therapy and selective serotonin reuptake inhibitor (SSRI) medications, such as sertraline and fluoxetine. These approaches, however, do not work for everyone.
Every day in the United States, approximately 17.5 veterans die by suicide, while 7% of veterans are diagnosed each year with post-traumatic stress disorder (PTSD). Against this backdrop, researchers at Texas A&M Health are helping advance a more personalized approach to treating PTSD.
A system developed by California-based Wave Neuroscience in collaboration with the research team of Dr. Kenneth S. Ramos at the Texas A&M Health Institute of Biosciences and Technology recently received FDA clearance. The technology maps brain activity associated with PTSD and uses those measurements to personalize treatment. The clinical findings are still being prepared for public dissemination, but preliminary results reported by the company suggest substantial improvements in PTSD symptoms.
PTSD can develop after exposure to events that go beyond ordinary stress, including combat, accidents, natural disasters, or other forms of violence. About 6% of people develop PTSD symptoms during their lifetimes, with substantially higher rates among women and veterans.
Since PTSD became an official diagnosis in 1980, common treatments have included talk therapy and selective serotonin reuptake inhibitor (SSRI) medications, such as sertraline and fluoxetine. These approaches, however, do not work for everyone.
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option.
scitechdaily.com
